<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515228</url>
  </required_header>
  <id_info>
    <org_study_id>CVRF2011-11</org_study_id>
    <nct_id>NCT01515228</nct_id>
  </id_info>
  <brief_title>Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)</brief_title>
  <official_title>Randomized Comparison of Dual Drug-Eluting Cilotax Stent and Everolimus -Eluting Stent Implantation for DE Novo Coronary Artery DisEase in Patients With DIABETES Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, MD, PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and effectiveness of coronary stenting
      with the Cilotax stent compared to the Xience Prime stent in the treatment of diabetic
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized multi-center trial of 300 patients will be enrolled at 7 centers in
      Korea. Following angiography, diabetic patients with significant diameter stenosis &gt;50% by
      visual estimation have documented myocardial ischemia or symptoms of angina, and eligible for
      stenting without any exclusion criteria will be randomized 1:1 to: a) Cilotax stent vs. b)
      Xience Prime stent. All patients will be followed for at least 1 year. Angiographic follow-up
      at 9-months is routinely recommended.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss</measure>
    <time_frame>at 9 month angiographic follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (ischemia-driven)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (ischemia-driven)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (by ARC definition)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in both in-stent and in-segment</measure>
    <time_frame>at 9 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis</measure>
    <time_frame>at 9 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>At discharge from the index hospitalization, an expected average of 3 days.</time_frame>
    <description>achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (ischemia-driven)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (ischemia-driven)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (ischemia-driven)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (ischemia-driven)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (ischemia-driven)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (ischemia-driven)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (by ARC definition)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (by ARC definition)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (by ARC definition)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Xience Prime stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>everolimus eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilotax stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel with cilostazol dual drug eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience Prime</intervention_name>
    <description>everolimus-eluting stent implantation</description>
    <arm_group_label>Cilotax stent</arm_group_label>
    <other_name>everolimus-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cilotax stent</intervention_name>
    <description>paclitaxel with cilostazol dual drug eluting stent implantation</description>
    <arm_group_label>Xience Prime stent</arm_group_label>
    <other_name>paclitaxel with cilostazol dual drug eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical:

          -  Diabetic patients with active treatment (oral agent or insulin)

          -  Patients with angina and documented ischemia or patients with documented silent
             ischemia

          -  Patients who are eligible for intracoronary stenting

          -  Age &gt; 20 years, &lt; 75 years

        Angiographic:

          -  De novo lesion

          -  Percent diameter stenosis ≥ 50%

          -  Reference vessel size ≥ 2.5 mm by visual estimation

        Exclusion Criteria:

          1. History of bleeding diathesis or coagulopathy

          2. Pregnant state

          3. Known hypersensitivity or contra-indication to contrast agent and heparin

          4. Limited life-expectancy (less than 1 year)

          5. ST-elevation acute myocardial infraction requiring primary stenting

          6. Characteristics of lesion: left main disease, in-stent restenosis, graft vessels

          7. Hematological disease (Neutropenia &lt; 3000/mm3), Thrombocytopenia &lt; 100,000/mm3)

          8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3times normal

          9. Renal dysfunction, creatinine ≥ 2.0mg/dL

         10. Contraindication to aspirin, clopidogrel or cilostazol

         11. Contraindication to Paclitaxel or everolimus

         12. Left ventricular ejection fraction &lt; 30%

         13. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period

         14. Non-cardiac co-morbid conditions are present with life expectancy &lt; 1 year or that may
             result in protocol non-compliance (per site investigator's medical judgment for
             example: oxygen dependent chronic obstructive pulmonary disease, active hepatitis or
             severe liver function or kidney disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol-Whan Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, MD, PhD.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>requiring drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

